There is a particular kind of advice that venture capitalists give founders. It tends to be strategic, pattern-matched, drawn from the aggregate experience of watching many companies from the outside. It is often useful. But it is rarely the advice of someone who has sat in the CEO chair during a restructuring, managed a board through a governance crisis, or navigated the regulatory labyrinth of a heavily regulated industry from the inside. Valeri Petrov has done all of these things — and he has done them not once, but across a career that spans more than 30 companies, multiple industries, and the entire private equity infrastructure of South-East Europe.
The Operator’s Path
Petrov’s career did not begin in venture capital. It began at Royal Dutch Shell, where he learned how large-scale industrial operations work from the inside. From there he moved to the CEO role at Orgachim, one of Bulgaria’s largest chemical companies, where he led the kind of operational transformation that most investors only read about in case studies. The trajectory continued through Global Finance, Bancroft Private Equity, and Axxess Capital — firms that were building the private equity infrastructure of South-East Europe at a time when the asset class barely existed in the region. Each role was operational, not advisory. Each required making decisions with incomplete information, managing stakeholders with conflicting interests, and delivering results in markets where the institutional frameworks that Western investors take for granted were still being constructed.
The Thirty-Board Thesis
When you have sat on more than 30 boards across industries — from chemicals to financial services, from manufacturing to technology — you develop a pattern recognition that is qualitatively different from the pattern recognition of a traditional VC. You learn that governance is not a compliance exercise but a competitive advantage. You learn that the difference between a company that survives a crisis and one that does not is almost never the product or the market — it is the decision-making architecture of the leadership team. You learn that the hardest problems in company building are not technical or commercial but organisational: how information flows, how incentives align, how boards function when the stakes are real and the answers are unclear. This is the lens that Petrov brings to Eleven Ventures — not the lens of someone who has observed companies, but the lens of someone who has operated them.
Healthcare at Eleven
At Eleven Ventures, Petrov heads healthcare investments — and healthcare is precisely the vertical where this operational depth matters most. Healthcare startups operate under constraints that most technology companies never encounter: regulatory approval cycles that can stretch for years, patient safety requirements that make “move fast and break things” not just inadvisable but potentially dangerous, reimbursement structures that determine commercial viability independently of product quality, and stakeholder ecosystems that include clinicians, hospital administrators, insurers, and regulators, each with their own decision criteria and timelines. An investor who has never navigated comparable complexity from the inside will struggle to add real value to a healthcare founder. An investor who has managed chemical plants, restructured industrial companies, and built private equity operations in emerging markets understands the texture of regulated, high-stakes environments in a way that no amount of deal flow can teach.
Why the Human × AI Conference
AI in healthcare is the highest-stakes application of artificial intelligence currently being deployed. The consequences of getting it wrong are not measured in lost revenue or reduced engagement but in misdiagnoses, delayed treatments, and compromised patient safety. This makes the question of responsible AI deployment in healthcare not just a technical challenge but a governance challenge — exactly the kind of challenge that Petrov’s career has prepared him to address. At the Human × AI Conference, he brings the operational investor’s perspective: not “how do we build AI systems that work?” but “how do we build organisations that deploy AI systems responsibly, in environments where the margin for error is measured in human outcomes?” It is a question that requires board-room scars, not just boardroom theory.
Implications
- For healthcare founders: The gap between building a working AI product and deploying it in a clinical environment is larger than most founders anticipate. Petrov’s operational lens — shaped by decades of navigating regulated, high-stakes industries — offers a framework for thinking about governance, compliance, and stakeholder management that is as important as the technology itself.
- For investors: Healthcare AI demands a different kind of due diligence — one that evaluates not just the model and the market but the organisational capacity to operate in regulated environments. Petrov’s 30-board track record demonstrates what operational value-add actually looks like when the portfolio company faces real governance complexity.
- For conference attendees: Expect a perspective on AI deployment that starts not with the technology but with the organisation deploying it — its decision-making architecture, its regulatory readiness, and its capacity to operate responsibly when the stakes are highest.
Valeri Petrov joins Human × AI on May 19, 2026, in Vienna.